NR3C1 and type 2 diabetes mellitus: Increased expression of GR has been observed in the liver of diabetic mice, while treatment with the GR antagonist-RU486-reversed the increase in the expression and attenuated the phenotype of T2D, supporting that the activation of GR may contribute to the development of T2D [119].